• CasNo:1809249-37-3
  • 分子式:C27H35N6O8P
  • 纯度:USP40,98%~102%
  • 分子量:602.58


Product Description
Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg disease Chemicalbook virus, and Middle East respiratory syndrome (MERS) and atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future

Remdesivir is a nucleoside analogue and is an inhibitor of RNA-dependent RNA polymerase (RdRp), which can inhibit viral nucleic acid synthesis against viruses. The current clinical research on Ebola virus infection is in phase II. MERS-infected mice performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that Remdesivir has a certain active effect on inhibiting the new coronavirus.

Remdesivir is a nucleoside analogue and is an RNA-dependent RNA polymerase (RdRp) inhibitor. It can synthesize by inhibiting viral nucleic acids.
A clinical Chemicalbook bed study for Ebola infection is currently in phase II.MERS-infected mice performed much better with this combination therapy, with reduced rplication and improved lung.

Biological activity:
Remdesivir (GS-5734) is a nucleoside analog with antiviral activity. In HAE cells, it has an EC50 value of 74 nM against SARS-CoV and MERS-CoV. In delayed brain tumor cells, it has antiviral activity against murine hepatitis virus. The EC50 value is 30 nM.
Factory supply Best purity 99% API USP/EP Remdesivir CAS 1809249-37-3 Leading GMP producer